Author

Michael M. F. Lahn

Observed names: M. Lahn, MICHAEL LAHN, MICHAEL M. LAHN, Michael Lahn, Michael M. Lahn

Observed institutions: University of Modena and Reggio Emilia, Eli Lilly (United States), German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Eli Lilly (Germany), Tongji Hospital, iOnctura SA (Switzerland), Huazhong University of Science and Technology, University of Bari Aldo Moro

ORCID: 0000-0001-9371-0316

Observed ORCID: 0000-0001-9371-0316

OpenAlex ID: A5101627113

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

2015 · Michael Lahn, Stephan Herbertz, et al. · Drug Design Development and Therapy · 616

PDF

TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma

2010 · Judit Anido, Andrea Sáez-Borderías, et al. · Cancer Cell · 602

PDF

Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma

2014 · Gianluigi Giannelli, Erica Villa, et al. · Cancer Research · 276

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

2019 · R.K. Kelley, E. Gane, et al. · Clinical and Translational Gastroenterology · 259

Blockade of TGF-β Signaling by the TGFβR-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma

2011 · Mengxian Zhang, Susanne Kleber, et al. · Cancer Research · 259

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

2014 · Jordi Rodon, Michael A. Carducci, et al. · Clinical Cancer Research · 243

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

2017 · Jonathan M. Yingling, William T. McMillen, et al. · Oncotarget · 190

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

2014 · Jordi Rodón, Michael Carducci, et al. · Investigational New Drugs · 110

PDF

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

2014 · Richard J. Kovacs, Giuliana Maldonado, et al. · Cardiovascular Toxicology · 109

PDF

TGF-β inhibitors for the treatment of cancer

2005 · Michael Lahn, Susanne Kloeker, et al. · Expert Opinion on Investigational Drugs · 84

Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

2013 · Ivelina Gueorguieva, Ann L. Cleverly, et al. · British Journal of Clinical Pharmacology · 79

TGF-β signalling-related markers in cancer patients with bone metastasis

2008 · Jose Baselga, Mace L. Rothenberg, et al. · Biomarkers · 70

Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology

2011 · B. Glimelius, M. Lahn · Annals of Oncology · 64

PDF

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

2020 · Gianluigi Giannelli, Armando Santoro, et al. · PLoS ONE · 61

PDF

Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome

2004 · Susanne Strand, Dennis Strand, et al. · Gastroenterology · 55

PDF

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

2014 · Ronald Natale, Fiona Blackhall, et al. · Journal of Thoracic Oncology · 50

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

2021 · James J. Harding, Richard K. Do, et al. · Cancer Medicine · 45

PDF

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

2015 · Armin Maier, Anne-Lise Peille, et al. · Cellular Oncology · 44

PDF

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

2014 · ALLEN COHN, MICHAEL M. LAHN, et al. · International Journal of Oncology · 43

PDF

The role of protein kinase C-alpha (PKC-α) in melanoma

2004 · Michael M. Lahn, Karen L. Sundell · Melanoma Research · 40

Association of Long-term Administration of the Survivin mRNA-Targeted Antisense Oligonucleotide LY2181308 With Reversible Kidney Injury in a Patient With Metastatic Melanoma

2010 · William G. Herrington, Denis C. Talbot, et al. · American Journal of Kidney Diseases · 34

Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments

2007 · Axel-Rainer Hanauske, Olaf Oberschmidt, et al. · Investigational New Drugs · 34

Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide

2010 · Sophie Callies, Valérie André, et al. · British Journal of Clinical Pharmacology · 30

PDF

Retrospective analysis of protein kinase C-beta (PKC-β) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas

2007 · Shuyu Li, Mark Phong, et al. · Biology Direct · 27

PDF

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

2009 · B. Glimelius, M. Lahn, et al. · Annals of Oncology · 25

Works count: 54

Citation count: 3,671

H-index: 25

I10-index: 36